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“The important thing is to not stop questioning.” (1)
dAlbert Einstein
Following the introduction of B-type natriuretic peptide
(BNP) and its amino-terminal equivalent (NT-proBNP),
the use of biomarkers for the evaluation and management of
heart failure (HF) has grown. Indeed, natriuretic peptide
testing for diagnosis and prognosis recently earned a Class I
Level of Evidence: A in the 2013 American Heart Associ-
ation/American College of Cardiology clinical practice
guidelines for HF (2). Although it took years to develop
such support, this is indeed the proper recognition of the
clinical role played by these important biomarkers.
See page 158
The studies that ultimately led to this recognition more
often than not indicated the value of BNP and NT-
proBNP. However, during this time, a great evolution
occurred in the standards for evaluating the merits of
biomarkers in HF: compared with earlier analyses (which
occasionally appear primitive, in retrospect), the standards
for assessment of novel biomarkers have become consider-
ably more complex. Newer assays appropriately have a higher
bar to surpass, but this is critical, as there are important
considerations of incremental cost and beneﬁt ratio from
their measurement.
To this point, more noteworthy than the ascendancy of
BNP or NT-proBNP in the same HF clinical practice
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speciﬁcally referring to galectin-3 and soluble(s) ST2. Both
biomarkers have a scientiﬁc rationale for their measurement
in patients with HF, and since early publications identiﬁed
them as candidate prognostic biomarkers in HF (3,4), both
have data showing their prognostic importance in a wide
range of patient types, including those at risk for HF,
and those with established left ventricular dysfunction (with
or without symptomatic congestion). Both galectin 3 and
sST2 also have regulatory approval for clinical use in a
broad range of markets worldwide, and both are commer-
cially available.
Importantly, analogous to the early BNP and NT-
proBNP experience, whereas galectin-3 and sST2 have
a biological rationale for use, and both have been shown to
be prognostic in HF, no head-to-head data exist with
respect to the prognostic information provided by these 2
novel assays. This latter point is not insigniﬁcant: differ-
ences between galectin-3 and sST2 are considerably greater
than those of the 2 natriuretic peptides, and whereas
both share a common category and indication for their
measurement, they are fundamentally different biomarkers
and provide different information. Therefore, understanding
their individual and collective merit is an important
exercise, given their regulatory approval and availability for
clinical use.
It is in this context that investigators from Barcelona
examined the comparative prognostic value of galectin 3 and
sST2 in a thorough manner. As shown by Bayes-Genis et al.
(5), in this issue of the Journal, when tested in 876 patients
with chronic, ambulatory HF (median age: 70 years, average
left ventricular ejection fraction: 34%), both biomarkers were
prognostic for adverse outcomes (including all-cause and
cardiovascular mortality, as well as hospitalization for HF)
when analyzed in a univariate manner. In adjusted models,
sST2 had improved discrimination, good calibration, and
considerably reclassiﬁed clinical risk for each outcome
measure; in contrast, galectin-3 did not survive adjustment
for baseline variables. In head-to-head comparisons, sST2
was more prognostic.
When considering the merits of the exploding number of
biomarkers available for testing in HF, we recently stated the
importance of careful evaluation of candidates for clinical
application (6), emphasizing the importance of comparative
analyses with statistical rigor. In this regard, it is worth
reviewing the methods by which a HF biomarker may be
evaluated, in order to understand the potential clinical
signiﬁcance of the present results comparing galectin-3
and sST2.
Among the factors to consider in the study of biomarkers
in HF are discrimination, calibration, and reclassiﬁcation
(summarized in Table 1); all are applied well in the present
study.
“Discrimination” is a statistical term that reﬂects the
ability of a prognostic tool to predict an event versus
nonevent; in contrast, “calibration” measures how much the
Table 1 Examples of Commonly Used Statistical Methods for Evaluation of Candidate Variables in Prognostic Studies
Methods Examples Results Strengths Weaknesses
Discrimination ROC analyses
Logistic regression
Area under the curve
C-statistic
Easy to understand
Allows for comparison of different
variables and additive value of
variables beyond a base model,
through statistical change in
discrimination
Ignores the potentially random
nature of prognosis
May be inﬂuenced by case mix of
the cohort studied and does not
take distribution of risk into
account
Ignores time to event and treats
drop outs as nonevents
May underestimate the
importance of variables when
added to robust base model
Calibration Hosmer-Lemeshow test
AIC
BIC
Brier score
Hosmer-Lemeshow test: goodness-
of-ﬁt model
AIC and BIC: information regarding
balance of model goodness of ﬁt
and complexity
The Brier score measures accuracy
of probabilities
Allow for assessment of model
overﬁtting, and in the case of the
AIC and BIC, judges balance
between parsimony and
statistical power
May lack sensitivity
(Hosmer-Lemeshow)
May be difﬁcult to execute and
difﬁcult to understand
(AIC, BIC, Brier score)
Reclassiﬁcation NRI
IDI
NRI: the balanced sum of
individuals correctly predicted as
having events or nonevents and
compared either pre-deﬁned
categories of risk or those
applied in a continuous model
of risk
IDI: Risk assessed in a continuous
fashion, comparable to the
“continuous” NRI
Provides clinical context
Particularly useful when pre-
deﬁned categories of risk exist,
to allow for assessment of “up-
classiﬁcation” and “down-
classiﬁcation” of risk as well as
informing potential for
misclassiﬁcation
When used with categories, NRI
result may be inﬂuenced by the
arbitrary choice of risk levels
In category-free analyses, NRI and
IDI may provide optimistic
results for relatively small
improvements in risk
AIC ¼ Akaike information criterion; BIC ¼ Bayesian information criterion; IDI ¼ integrated discrimination improvement; NRI ¼ net reclassiﬁcation improvement; ROC ¼ receiver-operating characteristic.
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occurrence of the outcome, and it is an important compo-
nent to validate models assessing discrimination.
The most commonly used way to evaluate the discrimi-
nation of a HF biomarker is to assess the area under the
receiver-operating characteristic curve, a balance of sensi-
tivity and speciﬁcity for a gold standard outcome; the area
under the curve is also known as the C-statistic, particularly
when used in logistic regression. The advantage of this
approach is the ability to compare changes in C-statistics
resulting from the addition or subtraction of variables to
a pre-existing model. However, small but statistically
signiﬁcant changes in the C-statistic may be clinically
irrelevant, and there is no generally agreed upon “clinically
important” improvement in C-statistics, creating challenges
for translating data into clinical practice. In some cases,
a valuable variable may provide little change to a very robust
baseline model, whereas lesser important variables may result
in substantial changes in a more unstable model. As well,
receiver-operating characteristic testing is most valuable
when an outcome is already present, such as for a diagnostic
test; use for prognosis is less trustworthy. To verify
discriminative results, calibration is an important next step.
A result may be signiﬁcant in discriminative models but not
sound if calibration is poor, such as the all-cause mortality
risk predicted by galectin-3 in this study.
To provide clinical relevance to results, “reclassiﬁcation”
measures have been introduced, with the net reclassiﬁcationimprovement or integrated discrimination improvement
approaches applied most often. These methods essentially
total the overall change in risk prediction from the addition
of results to a model through the sum of correctly upward-
classiﬁed events and downward-classiﬁed nonevents, sub-
tracted by the proportions of incorrectly downward-classiﬁed
events and upward-classiﬁed nonevents. The value of
reclassiﬁcation analyses is that they provide immediately
clinically useful information for assessing the potential
impact of a novel biomarker when applied to a patient
population that it may be tested in. Limitations of reclas-
siﬁcation analyses include the fact that a lack of gold stan-
dard categories of risk may result in the use of arbitrary risk
strata.
In the analysis by Bayes-Genis et al. (5), change in the
C-statistic (discrimination) was signiﬁcant when sST2 was
added to a strong clinical model for predicting all-cause
mortality, cardiovascular mortality, the combination of
both outcome measures, as well as for death or HF hospi-
talization; galectin 3 showed modest comparable perfor-
mance. That said, it is worth noting the 95% conﬁdence
intervals of the C-statistic overlapped between sST2 and
galectin-3; in this regard, superiority for sST2 is not
necessarily conclusive. However, calibration measures were
superior for sST2 versus galectin-3. Perhaps most clinically
relevant and most signiﬁcant, in this cohort, sST2 reclassi-
ﬁed risk by a substantial degree, whereas galectin 3 did not.
In fact, galectin-3 actually misclassiﬁed risk in those patients
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markers in this study favored sST2.
This study has little to assail in terms of methodologic
approach, with results that send a clear message. However,
there are limitations worth emphasizing. First, it is a rela-
tively small analysis of a generally male population, with
a wide range of left ventricular function. Whereas study
participants were nearly always taking angiotensin-
converting enzyme inhibitors/angiotensin II receptor
blockers or beta-adrenergic blockers, we are not provided the
doses being administered; furthermore, only 39% were
taking mineralocorticoid receptor antagonists, and a low
percentage had received cardiac resynchronization therapy
and/or implantable cardioverter-deﬁbrillators. These differ-
ences make validation of these results in a broad range of
other patient types important. Moreover, the analysis only
examined a single measurement of both biomarkers; serial
measurement adds considerable statistical and clinical value
for prognostic biomarkers and may have affected the results
of this analysis as happened in recent analyses of galectin 3
(7). Finally, whereas this analysis found sST2 prognostically
meaningful, translating prognostic merit to a strategic clin-
ical response was not explored, something we should all
hope to see with promising HF biomarkers in the future.
Whereas the results of this excellent study do not shut the
door on galectin-3, they should make us take pause, just as
much as any other novel biomarker being evaluated for use
in our patients. The rigorousness of this analysis is a ﬁne
example of the evolution in comparative biomarker studies
and how they may inform a path forward to clinical care. As
the use of biomarkers expands for the care of our patients,
we should never stop questioning and improving how we
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